Tamoxifen is an antagonist of the Estrogen receptor in breast tissue via its active metabolite, 4-hydroxytamoxifen.

Tamoxifen is the usual endocrine (anti-estrogen) therapy for ER+ Breast cancer in pre-menopausal women, and is also a standard in post-menopausal women although aromatase inhibitors are also frequently used in that setting.

관련링크

• 20년간 유방암 발생률 평균 30% 감소시킨 타목시펜 2014-12-18

Incoming Links #

Related Medical Conditions (MedicalCondition 0) #

• Breast cancer

Related Articles (Article 1) #

• COPS5
• Companion diagnostic
• Triple-negative breast cancer

Related Codes (Code 2) #

• DiffBind

Related Books (Book 3) #

• Robbins and Cotran Pathologic Basis of Disease

Related Medical Scholarly Articles (MedicalScholarlyArticle 4) #

• Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer

Suggested Pages #

• 0.139 HMEC
• 0.091 CDH1
• 0.089 Trastuzumab
• 0.043 MYC
• 0.042 Drug discovery
• 0.042 Bevacizumab
• 0.035 Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
• 0.030 Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
• 0.026 Identification of Biomarkers for Breast Cancer Using Databases
• 0.026 KOHBRA
• More suggestions...